Antifungal Antagonism Screening

NCATS早期翻译处(ETB)主持了一项广泛而全面的计划，以发现针对罕见疾病的候选药物和探索人类基因组功能的药理学工具。ETB进行研究，以了解推动基础研究发现转化为对人类健康的切实改善的潜在原则。 在本报告所述期间，合作小组致力于开发一种高通量筛选试验，以确定降低四种主要人类真菌病原体(白色念珠菌、光滑念珠菌、新生念珠菌和烟曲霉菌)对最常用的抗真菌药物(唑类、两性霉素B和棘球菌素)敏感性的化合物。这将确定一份可能破坏当前使用的抗真菌药物临床疗效的药物清单。

The NCATS Early Translation Branch (ETB) hosts a broad and comprehensive program for the discovery of drug candidates directed towards rare diseases and pharmacological tools to probe the function of the human genome. ETB conducts research to understand the underlying principles driving the translation of basic research discoveries into tangible improvements in human health. During the reporting period, the collaborative team worked to develop a high-throughput screening assay to identify compounds that reduce the susceptibility of four major human fungal pathogens (C. albicans, C. glabrata, C. neoformans and A. fumigatus) to the most commonly used classes of antifungal drugs (azoles, amphotericin B and echinocandins). This will identify a list of medications that may undermine the clinical efficacy of currently used antifungal drugs.